Wong Lab Publications

Targeting a Glioblastoma Cancer Stem-Cell Population Defined by EGF Receptor Variant III.
Cancer Research. Emlet, D. R., Gupta, P., Holgado-Madruga, M., Del Vecchio, C. A., Mitra, S. S., Han, S., Li, G., Jensen, K. C., Vogel, H., Xu, L. W., Skirboll, S. S., Wong, A. J. 2014; 74 (4): 1238-1249

EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms.
Oncogene. Del Vecchio C. A., Giacomini C. P., Vogel H., Jensen K. C., Florio T., Merlo A., Pollack J. R., Wong A. J. 2013; 32 (21): 2670-2681

Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types.
PLoS genetics. Giacomini C. P., Sun S., Varma S., Shain A. H., Giacomini M. M., Balagtas J., Sweeney R. T., Lai E., Del Vecchio C. A., Forster A. D., Clarke N., Montgomery K. D., Zhu S., Wong A. J., van de Rijn M., West R. B., Pollack J. R. 2013; 9 (4)

Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas.
J Neurooncol. Li G., Mitra S. S., Monje M., Henrich K. N., Bangs C. D., Nitta R. T., Wong A. J. 2012; 108 (3): 395-402

A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors.
Oncogene. Piccione E. C., LIEU T. J., Gentile C. F., Williams T. R., Connolly A. J., Godwin A. K., Koong A. C., Wong A. J. 2012; 31 (24): 2953-2967

Epidermal Growth Factor Receptor Variant III Contributes to Cancer Stem Cell Phenotypes in Invasive Breast Carcinoma.
Cancer Research. Del Vecchio C. A., Jensen K. C., Nitta R. T., Shain A. H., Giacomini C. P., Wong A. J. 2012; 72 (10): 2657-2671

Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.
Expert Rev of Vaccines Del Vecchio C. A., Li G., Wong A. J. 2012; 11 (2): 133-144

Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma.
Proc Natl Acad Sci USA. Monje M., Mitra S. S., Freret M. E., Raveh T. B., Kim J., Masek M., Attema J. L., Li G., Haddix T., Edwards M. S., Fisher P. G., Weissman I. L., Rowitch D. H., Vogel H., Wong A. J., Beachy P. A. 2011; 108 (11): 4453-4458

The role of the c-Jun N-terminal kinase 2-alpha-isoform in non-small cell lung carcinoma tumorigenesis.
Oncogene. Nitta R. T., Del Vecchio C. A., Chu A. H., Mitra S. S., Godwin A. K., Wong A. J. 2011; 30 (2): 234-244

Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.
Curr Opin Mol Ther. S Del Vecchio C. A., Wong A. J. 2010; 12 (6): 741-754

Development of an EGFRvIII specific recombinant antibody.
BMC Biotechnol. Gupta P., Han S., Holgado-Madruga M., Mitra S. S., Li G., Nitta R. T., Wong A. J. 2010; 10

Pineal Parenchymal Tumor of Intermediate Differentiation: Clinicopathological Report and Analysis of Epidermal Growth Factor Receptor Variant III Expression.
Neurosurgery. Li G., Mitra S., Karamchandani J., Edwards M. S., Wong A. J. 2010; 66 (5): 963-968

Measuring the Consitutive Activation of C-Jun N-Terminal Kinase Isoforms.
Methods Enzymol. A Nitta R. T., Badal S. S., Wong A. J. 2010; 484: 531-548

The Epidermal Growth Factor Variant III Peptide Vaccine for Treatment of Malignant Gliomas.
Neurosurg Clin N Am. Li G., Mitra S., Wong A. J. 2010; 21 (1): 87-93